HomePipelinePNB-101

Targeted oncology

PNB-101

IND ready

A targeted molecule for Gastrin-Related Cancers, with small cell lung, liver and Stomach Cancer as secondary indications. Lung and liver tissue show the highest CCK-B receptor expression.

Indications

Each indication opens its study.

Stage of development

  • PNB-101

    Lung CancerCCK-B pathway inhibition

  • PNB-101

    Liver CancerCCK-B pathway inhibition

Graph of the stage of development of each PNB-101 programme. Horizontal axis: clinical development stage, from Preclinical to Phase 3. Vertical axis: molecule and indication. Each marker opens the programme's indication, biological action, stage and status.
Target and mechanism
CCK-B (CCK2/gastrin) receptor blocker. Its chlorinated sister molecule, PNB-102, is suited to CNS applications.
Key findings

In a xenograft study with the human Lung Cancer cell line NCI-H727, oral dosing inhibited tumour growth by more than 80% in responders after 28 days.

In the C38 murine lung cell line, in vitro anti-cancer activity exceeded that of the reference CCK2 antagonist CI-988.

Development

Two-step synthesis from economical raw materials. ICH toxicology studies are scheduled to begin after PNB-081.

Intellectual property
Patents filed in the US, Europe and rest of world; PCT application filed and granted; USPTO patent issued 28 December 2014.

Interested in a programme?

PNB Vesper welcomes discussions on clinical development, licensing, co-development and investment for any molecule in the pipeline.